SUN 131

Drug Profile

SUN 131

Alternative Names: SUN131

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Senju Pharmaceutical
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Ocular inflammation

Most Recent Events

  • 22 Aug 2017 Phase-III clinical trials in Ocular inflammation (In children, In adults, In the elderly) in USA (Transdermal) (NCT03248440)
  • 07 Apr 2017 No recent reports of development identified - Phase-II for Ocular inflammation in USA (Transdermal)
  • 01 Oct 2014 Phase-II clinical trials in Ocular inflammation in USA (Transdermal) (NCT02338648)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top